INTRODUCTION
Developmental dysplasia of the hip (DDH) is characterised by abnormal development of the hip joint and presents with varying severity from mild uncovering of the femoral head to complete dislocation of the joint. 1 It is the most common developmental musculoskeletal anomaly, with population-weighted average incidence that ranges strongly with ethnic background from 0.06 per 1000 live births in Black Africans to 76.1 per 1000 live births in Native Americans, 2 and with an incidence in the UK European population of 3.6 per 1000. DDH is a complex disorder, with known associations including female sex, first-born, breech presentation, and family history. 2 There is a 7-fold increase in the incidence between siblings and a 10-fold increase in the parents of probands compared to the general population, 3 and a concordance rate of 41% between identical twins versus 3% in dizygotic twins. 4 Whilst DDH is heritable, its genetic architecture remains poorly characterised. Several linkage scans and candidate gene studies have implicated possible associated genetic variants, including in GDF5, 5 but to date no replicated loci of genome-wide significance have been identified. 2, [6] [7] [8] [9] A recent genomewide association study (GWAS) of 386 patients and 558 controls in the Han Chinese population suggested an association with variation in UQCC (odds ratio (OR) 1.35, P=3.63x10 -6 ), a gene adjacent to GDF5. 10 Morphological abnormalities of the hip such as DDH are also recognised as risk factors for the development of secondary degenerative change of the hip, 11, 12 and commonly result in hip replacement in adult life. 12, 13 Idiopathic hip osteoarthritis (OA) is very common and has a substantial heritable component, 14 and may share common genetic aetiology with DDH. 2, 7, 15 Systematic examination of genome-wide variation in DDH in larger sample sizes is necessary to clarify its heritable biology and inform mechanism-driven preventative strategies. However, sample collection for uncommon diseases can be challenging and time-consuming, as attested by the relative paucity of sample sets for genetic studies of DDH. Routinely-collected national clinical audit datasets (NCAs) present an opportunity for efficient case ascertainment in genetic epidemiology. The National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man (NJR, http://www.njrcentre.org.uk/) was established in 2003 to collect audit data on all hip and knee replacement surgery in these regions, for which it has a completeness rate of 97% (http://www.njrreports.org.uk/Data-Completeness-andquality). As at December 31 st 2014, the dataset held information on 711 765 primary hip replacement procedures, including data on the diagnostic indication for surgery. We used the NJR as a caseascertainment tool to conduct a nationwide genome-wide association scan to characterise the genetic architecture of DDH. We examine the heritable contribution to DDH, and use fine-mapping and genebased enrichment approaches to identify likely causal variants and genes. Finally, we use independent OA-datasets to examine for shared genetic aetiology between DDH and hip OA.
PATIENTS AND METHODS

NCA-based recruitment strategy
Between January 2013 and April 2014, 5411 adults (4095 female) from a total NJR database of 711 765 procedures (0.76%) had undergone a hip replacement for the recorded indication of hip dysplasia and were invited to participate in the screening program (figure 1, and supplementary section 1a.). Subsequent screening comprised filtering by self-reported questionnaires for UK European ancestry and a childhood history of idiopathic DDH (supplementary section 1.a and table S1). Following screening, 1091 individuals confirming both UK European ancestry and idiopathic DDH diagnosed in childhood were invited to return by post a saliva sample for DNA extraction and genotyping. Of these, 907 (803 female) returned a sample. The sex distribution of the responding subjects was similar to that of the DDH population in the UK. 2 Radiographic validation of the DDH phenotype was conducted using a plain pelvic radiograph preceding hip replacement retrieved electronically via the National Data Sharing Network (http://www.image-exchange.co.uk/) in a convenience subset of 231 (25%) subjects completing saliva return. The age and sex distribution of the validation subset was similar to the 907 that returned a saliva sample. Radiographic analysis confirmed DDH in 224/231 (97%, supplementary section 1.a). Non-DDH cases were excluded from further analysis. Samples from 900 subjects proceeded to DNA extraction and quality control. In 834 samples DNA yield was sufficient to progress to genome-wide genotyping.
The replication cohort comprised 838 children (725 female) from the UK DDH case control consortium recruited at 18 English hospitals (supplementary section 1.a and table S2) and 225 adults (220 female) with DDH recruited at the Royal National Orthopaedic Hospital. In addition, 66 cases (59 female) from the NJR discovery cohort of insufficient DNA yield for genome-wide genotyping were also included in the replication cohort. Subject overlap between the discovery and replication populations, and between the replication cohorts was excluded using individual patient identifiers and by cross-referencing to the NJR dataset. Case duplication was excluded in the discovery cohort at both subject ID and genotype quality control stages. Power was calculated by fixing the sample size to our post-quality control (QC) sample size and gave >80% power to detect common variants with moderate effect size at genome-wide significance (p=5.0x10 -8 , supplementary section 1.b and figure S1). Following QC checks at both the sample and single nucleotide polymorphism (SNP) level (supplementary section 1.b), 256 867 variants were tested using the likelihood ratio test under an additive genetic model for association with DDH in 770 (693 female) DDH cases and 3364 (3048 female) controls using SNPTEST v2.2. 16 Independent variants (p<1x10 -4 ) (supplementary section 1.b) in the discovery set were selected for replication. De novo genotyping for these SNPs in 1129 (1004 female) replication cases was conducted using the iPLEX® Assay and the MassARRAY® System (Agena Bioscience, Inc). Case-control association analysis versus 4652 (2527 female) controls was performed under an additive genetic model. Finally, a fixed-effects meta-analysis was conducted across the discovery and replication datasets, comprising a total of 1899 cases and 8016 controls. Conditional single-variant association analyses were used to identify statistical independence. A variant was considered independent of the index SNP if the pre-and post-conditioning p-value difference was lower than two orders of magnitude.
Heritability analysis
We estimated the heritability of DDH using the genome-wide analysis dataset using genetic complex trait analysis (GCTA) and phenotype correlation genotype correlation (PCGC), assuming a DDH prevalence of 3.6 per 1000 live births in the UK, 2 and using a minor allele frequency (MAF) cut-off of 0.01 (supplementary section 1.c).
Fine-mapping
In order to fine-map the replicating association signals, we imputed variant genotypes locally using 1000 Genomes Project 17 combined with UK10K Project 18 data as the reference panel (supplementary section 1d.). We then applied a method that assigns a relative "probability of regulatory function" (PRF) score among candidate causal variants, reweighting association statistics based on epigenomic annotations, and delineating the 95% probability set of likely causal variants (supplementary section 1.d).
Gene-based enrichment analyses
In order to quantify the degree of association each gene has with the phenotype and understand the potential functional effects of the identified variants, we used the GWAS results to perform gene-based enrichment analyses in MAGMA v1.03 to identify the joint association of all markers in a given gene with the phenotype (supplementary section 1.e).
Genetic overlap with hip OA
Polygenic risks scores were created for all genotyped participants to test for shared genetic aetiology with idiopathic hip OA. Two independent UK cohorts were used for these analyses: 3266 cases with hip OA versus 11 009 controls from the arcOGEN study; and 2396 cases with International Classification of Diseases (ICD) 10 coded hip OA versus 9593 controls from the UK Biobank (supplementary section 1.f). High-resolution polygenic risk scores were made using evenly spaced pvalue thresholds (Pt) between 0.001 to 0.5, at increments of 0.0001, to produce 4991 risk thresholds.
Data Availability
Genome-wide genotype data of the DDH cases and UKHLS controls have been deposited to the European Genome-Phenome Archive (www.ebi.ac.uk/ega/home, DDH accession numbers: EGAD00010000766 and EGAS00001000916; UKHLS accession numbers: EGAD00010000891 and EGAS00001001232) and of the DDH NJR cases to the NJR data archive (www.njrcentre.org.uk).
RESULTS
The heritable component of DDH
Using GCTA we found that common-frequency autosomal SNPs explain 55% (±se=6%, p<0.0001) of the liability-scale heritability of DDH. The heritability estimate by PCGC was very similar to that identified by GCTA (supplementary table S4). The heritability estimate was also similar (54.7±5.8%) when the analysis was repeated using sex as a covariate.
Discovery GWAS
Genome-wide analysis showed an excess of signals in the discovery case-control population (figure 2).
A total of 53 SNPs comprising 25 independent signals showed suggestive evidence for association with DDH at p<1x10 -4 compared to 3 independent variants expected under the null hypothesis of no association (binomial p=9.57x10 -17 , supplementary . When the replication analysis was performed excluding the 66 NJR subjects that failed genome-wide genotyping QC, the findings were similar (data not shown).
Meta-analysis
At meta-analysis, 20 SNPs were associated with DDH with the same direction of effect in both the discovery and replication analysis. Three SNPs in the same region of chromosome 20 showed association with DDH at genome-wide significance: rs143384 in GDF5 ( figure 3A, effect Two further independent signals showed evidence of replicating association with DDH, although this did not reach genome-wide significance at meta-analysis: rs4740554 (effect allele C, EAF 0.10, OR p=4.38x10 -6 ) (figure 3B and 3C, and Table 1 ). rs4740554 and rs4919218 explained 0.36% and 0.24% of phenotypic variance (λ s = 1.02 and 1.01), respectively (supplementary figure S2 ).
Fine-mapping
For the GDF5 signal, five variants were included in the 95% probability set of being causal. Among these, both rs143384 and rs143383 have high epigenomic scores as they are located in the 5' UTR of GDF5, have high nucleotide sequence conservation, and overlap DNase hypersensitivity and activating histone marks. Considering annotations and association statistics p-values together, rs143384 had a >99% likelihood of being the causal variant, assuming only 1 variant as causal.
Gene-based enrichment analyses
After adjusting for the family-wise error rate (FWER), we found five genes that were associated with DDH susceptibility: GDF5, UQCC1, MMP24, RETSAT and PDRG1 (p=9.24x10 -12 , p=1.86x10 -10 , p=3.18x10 -9 , p=3.70x10 -8 and p=1.06x10 -7 , respectively; Supplementary table S8 ). To exclude association through GDF5, we repeated the analysis by removing GDF5 and all genes remained associated with DDH.
Shared genetic aetiology with hip OA
We found little evidence for shared genetic aetiology between DDH and hip OA. The best fit polygenic risk score for hip OA in the arcOGEN and ICD-10 coded hip OA in the UK Biobank datasets explained ~0.05% and 0.35%, respectively, of the variation in DDH susceptibility (FWER P>0.05, supplementary figure S3 ).
DISCUSSION
We used case-ascertainment by NCA database search and postal recruitment to facilitate the largest genome-wide association scan for DDH to date. We found that the heritable component of DDH due to common autosomal variants is approximately 55%, consistent with the complex nature of the disease.
We establish variation within GDF5 on chromosome 20 as robustly associated with DDH susceptibility, with the variant rs143384 as the causal signal by fine-mapping, although GDF5 variation makes only a small contribution to overall DDH heritability. Through gene-based enrichment analyses we identify GDF5, UQCC1, MMP24, RETSAT and PDRG1, as independently associated with DDH susceptibility.
Previous studies examining the epidemiology of DDH within families using epidemiological linkage approaches have demonstrated that heritable factors contribute between 50% and 85% of the total liability of disease, 3, 19, 20 depending on population ethnicity. Here, we used dense genome-wide genotyping data to estimate the heritable risk of DDH amongst unrelated individuals of UK European ancestry in the general English population. Our estimate of DDH heritability attributable to variation within autosomal chromosomes was broadly similar to the estimates derived from linkage analyses. 2 When the heritability analysis was stratified by chromosome, we found that the X-chromosome contributed a similar amount to overall DDH heritability as the autosomes ( Supplementary Fig. 4 ), and we identified no individual chromosome X signals. Taken together, these data suggest that although DDH is strongly sex-linked, this is not substantially due to variation in genomic DNA.
The gene GDF5 encodes growth differentiation factor 5 (GDF5), belonging to the transforming growth factor beta superfamily. 21 GDF5 is required for normal bone and joint development by promoting cartilage condensation and increasing the size of the skeletal elements through proliferation within epiphyseal cartilage. 22 Two GDF5 variants, rs143383 and 143384, have previously shown suggestive association with DDH in unreplicated candidate gene studies in Asians and in Europeans. 5, 23 Here we validate and extend these findings at the genome-wide level and with robust replication. These variants are in high linkage disequilibrium (r 2 =0.82, D'=0.99), and were both directly genotyped in this study.
Our data implicate rs143384 as the lead variant, with the rs143383 association with DDH being two orders of magnitude weaker. Subsequent fine-mapping of the GDF5 locus using Roadmap Epigenome annotations with imputation using 1000 Genomes and UK10K Project data also identified rs143384 as the likely causal variant. Chen et al, 24 have shown that the GDF5 locus contains many separate regulatory elements that control expression of the gene at different joint sites, and that these flanking regions are large. Interrogation of the GTEx database indicates that rs143384 is an expression quantitative trait locus (eQTLs) for multiple genes across various tissues (supplementary table 9 ). 25, 26 This annotated function provides novel opportunities for investigation of the role of GDF5 as a candidate target for DDH prevention.
Gene-based enrichment analysis can boost power to identify contributing loci by combining information across multiple SNPs co-localised at the gene level. Here, we found associations with the GDF5, UQCC1, MMP24, RETSAT and PDRG1 genes. UQCC1 gene encodes a trans-membrane protein ubiquinol-cytochrome c reductase complex chaperone, which is structurally similar to the mouse basic fibroblast growth factor repressed ZIC-binding protein. 27 In humans, polymorphisms in this gene have been associated with DDH, 10 bone size, 28 height, 29 and hip axis length. 30 MMP24 encodes a member of the peptidase M10 family of matrix metalloproteinases (MMPs) involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development and tissue remodelling. 31 Polymorphisms within MMP24 have also been associated with height variation in childhood. 32, 33 RETSAT codes for retinol saturase, an enzyme centrally involved in the metabolism of vitamin A. 34 Retinoic acid signalling is essential for normal limb bud development, including bone and cartilage formation, 35 and provides a further candidate target in DDH pathogenesis.
This study has limitations. The patients recruited in the discovery cohort were adults who had undergone a hip replacement for progressive symptoms related to an underlying diagnosis of hip dysplasia, as identified through the NJR. To mitigate against misclassification bias in case-ascertainment we employed a stepwise filtration approach that subsequently validated with high concordance against examination of plain radiographic images. The female-to-male case ratio in our final NJR DDH cohort was similar to that expected in the general DDH population in the UK, 2 and contrasts with that found in idiopathic OA of the hip. 36 Previous studies have also demonstrated the contribution of DDH as a risk factor for secondary OA, 11, 12, 37 and that OA susceptibility genes influence the association between hip morphology and OA. 15, 38, 39 We therefore examined whether we were simply detecting OAassociated loci in our DDH discovery cohort, as case identification required NJR registration for a hip replacement. Polygenic risk scores derived using independent hip OA cohorts predicted only a small amount of the genetic variability in the DDH discovery population, suggesting only limited common genetic aetiology between the diseases. Finally, our replication cohorts mainly comprised independent populations of children recruited prospectively with a firm diagnosis of DDH, and in whom the oddsratio of association for the primary variant signal was similar to that found in the NJR-discovery sample.
In summary, the results of this largest study of DDH to date provide a comprehensive picture of its complex genetic architecture, the contribution of common variants to its heritability, and establishes the first robust DDH genetic locus. We also demonstrate the utility of national clinical audit-based case ascertainment and recruitment for genetics and genomics studies using a strategy that is transferrable to other complex diseases in which large-scale datasets are held. Each filled circle represents the p value of analysed variants (as -log 10 values) plotted against their physical position (NCBI Build 37). The p value at the discovery stage and combined discovery and replication cohorts is represented by a purple circle and diamond, respectively. The rest variants in the region are coloured depending on their degree of correlation (r 2 ) with the index variant according to a scale from r 2 =0(blue) to r 2 =1(red). Underneath, gene annotations from the UCSC genome browser. 
SNP ID (chromosome:position)
Effect
